Ligand Pharmaceuticals Incorporated is reaffirming its 2024 financial guidance. The Company expects 2024 royalties ranging from $90 million to $95 million, sales of Captisol to range from $25 million to $27 million, and contract revenue ranging from $15 million to $20 million. These revenue components result in total revenue forecast of $130 million to $142 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85 USD | -1.14% | -2.61% | +19.01% |
13/05 | Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing | MT |
08/05 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.01% | 152.6Cr | |
+39.22% | 73TCr | |
+30.57% | 59TCr | |
-7.85% | 35TCr | |
+15.48% | 32TCr | |
-0.12% | 27TCr | |
+12.55% | 24TCr | |
+6.65% | 20TCr | |
-6.09% | 20TCr | |
-3.37% | 16TCr |
- Stock Market
- Equities
- LGND Stock
- News Ligand Pharmaceuticals Incorporated
- Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024